A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients

NCT00319917 ↗

Phase 4 Completed 123 enrolled Astellas Pharma Inc

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to assess the efficacy on joint damage and safety in RA patients treated with DMARDs in a double blind, placebo controlled study.

Timeline

Start: 2006-04
Primary completion: 2008-10
Completion: 2008-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tacrolimus	Small molecule	—	Oral

A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients

Summary

Timeline

Drugs

Indications